Bone Drugs Pose No Clear Threat To Heart: FDA

Law360, New York (November 12, 2008, 12:00 AM EST) -- The U.S. Food and Drug Administration has announced that there appears to be no significant connection between the class of bone disease medications known as bisphosphonates and an increased risk of irregular heartbeat.

After a yearlong review of the drugs, the FDA released a statement about its findings on Wednesday, writing, “across all studies, no clear association between overall bisphosphonate exposure and the rate of serious or non-serious atrial fibrillation was observed.”

“Increasing dose or duration of bisphosphonate therapy was also not associated with an increased...
To view the full article, register now.